Table 3.
Phase III clinical trials of Id vaccination in follicular lymphoma.
| NCI/biovest | Genitope | Favrille | |
|---|---|---|---|
| Production of Id protein | Hybridoma | Recombinant | Recombinant |
| Isotype of Id | IgM or IgG | IgG | IgG |
| Pre-vaccine therapy | PACE | CVP | Rituximab |
| Pre-vaccination status | CR | CR or PR | CR, PR, or SD |
| Randomized patients | 117 | 349 | 287 |
| Primary endpoint | DFS | PFS | TTP |
| Results | p = 0.047 | NS | NS |
| Reference | Schuster et al. (2011) | Levy et al. (2008) | Freedman et al. (2009) |
CR, complete response; CVP, cyclophosphamide, vincristine, and prednisone; DFS, disease-free survival; Id, idiotype; NS, not significant; PACE, prednisone, doxorubicin, cyclophosphamide, and etoposide; PFS, progression-free survival; PR, partial response; SD, stable disease; TTP, time to progression.